EUVIMEDEUVIMED entdecken
Crossref

Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections

Samar Hikmat, Alison Boast iD, Nigel Curtis, Amanda Gwee

Journal of Antimicrobial Chemotherapy · 03.02.2025 · 80 (2) · 409-412

DOI: 10.1093/jac/dkae423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 21.11.2024. Verfasst von Samar Hikmat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine and Infectious Diseases, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Arthritis, Infectious, Cephalexin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cefalexin, a first-generation cephalosporin, is commonly used as oral continuation therapy for paediatric bone and joint infections (BJIs). The standard four times daily cefalexin dose makes treatment adherence challenging. A pharmacokinetic modelling study found that a cefalexin dose of 45 mg/kg (maximum 1.5 g) three times daily achieves the same pharmacodynamic target.

Objectives

To evaluate the efficacy and tolerability of three times daily cefalexin dosing in children with BJIs. Patients and methods Retrospective audit of children aged 1–18 years who received cefalexin at a dose of 40–50 mg/kg (maximum 1.5 g) three times daily as oral continuation therapy for a haematogenous BJI at a quaternary paediatric hospital in Australia over a 4 year period (January 2019 to December 2022).

Results

Of 149 children with BJIs treated with three times daily cefalexin dosing, the majority (147/149; 99%) achieved cure, with two experiencing recurrence of their infection. Most children tolerated the higher cefalexin dose; 4 children experienced gastrointestinal symptoms and 13 developed neutropenia, which was mild in most cases with no associated complications.

Conclusions

A reduced frequency dosing regimen using a high cefalexin dose of 45 mg/kg (maximum 1.5 g) three times daily is effective and well tolerated in most children with BJIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsArthritis, InfectiousCephalexinHumansChildChild, PreschoolRetrospective StudiesInfantMaleFemaleAdolescentTreatment OutcomeAustraliaDrug Administration ScheduleAdministration, Oral

Substanzen

Anti-Bacterial AgentsCephalexin

Autor:innen und Institutionen

  • Department of General Medicine and Infectious Diseases, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
  • Antimicrobials and Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

ORCID-Profile: Alison Boast

Förderung

  • NHMRC

Zitieren

APA

Hikmat, S., Boast, A., Curtis, N., & Gwee, A. (2025). Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections. Journal of Antimicrobial Chemotherapy, 80(2), 409-412. https://doi.org/10.1093/jac/dkae423

Vancouver

Hikmat S, Boast A, Curtis N, Gwee A. Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections. Journal of Antimicrobial Chemotherapy. 2025;80(2):409-412. doi:10.1093/jac/dkae423

BibTeX
@article{Hikmat2025,
  author = {Hikmat, Samar and Boast, Alison and Curtis, Nigel and Gwee, Amanda},
  title = {Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {2},
  pages = {409--412},
  doi = {10.1093/jac/dkae423}
}
Kostenlos starten →